Compare IMOS & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMOS | ANAB |
|---|---|---|
| Founded | 1997 | 2005 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2007 | 2015 |
| Metric | IMOS | ANAB |
|---|---|---|
| Price | $39.82 | $64.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $68.10 |
| AVG Volume (30 Days) | 37.7K | ★ 442.0K |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | ★ 1.64% | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $234,603,000.00 |
| Revenue This Year | $20.87 | N/A |
| Revenue Next Year | $4.97 | $43.04 |
| P/E Ratio | $158.35 | ★ N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $12.78 | $15.32 |
| 52 Week High | $45.43 | $63.47 |
| Indicator | IMOS | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 54.97 | 68.28 |
| Support Level | $16.81 | $43.67 |
| Resistance Level | $45.24 | N/A |
| Average True Range (ATR) | 1.73 | 3.61 |
| MACD | -0.13 | 0.67 |
| Stochastic Oscillator | 55.18 | 88.63 |
ChipMOS TECHNOLOGIES Inc is engaged in the research, development, manufacturing, and sale of high-integration and high-precision integrated circuits and related assembly and testing services. The company's segments include Testing, Assembly, Testing, and Assembly for LCD, OLED, and other Display Panel Driver Semiconductors (LCDD), Bumping, and others. It derives a majority of its revenue from Taiwan followed by Japan, the People's Republic of China, Singapore, and others.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).